Peking University Biologics (PKU BIO) and Norwich Investment Limited (Norwich) announced a Strategic Cooperation Agreement to promote the business development of both parties by establishing a long-term, comprehensive strategic partnership to achieve complementary advantages, resource sharing, and common business development.

PKU BIO is a leading biopharmaceutical CDMO professional organization well established in the Hefei Chaohu Economic Development Zone, while Norwich is an investment holding company established in BVI.

According to the Agreement, Norwich will introduce and refer PKU BIO to any potential investors via its vast project resources in the pharmaceutical industry while making its investment in the pharmaceutical industry projects, whereas PKU BIO may, as a partner of Norwich, provide production and research consulting services to the said potential investors. Moreover, Norwich may hire a team of experts from PKU BIO as an investment consultant to participate in project research and evaluation, issue relevant project evaluation reports, and assist Norwich in completing any project investment and financing. Additionally, Norwich will provide relevant information on the resources of the biopharmaceutical-related enterprise to PKU BIO, assist PKU BIO in supplier screening, and provide the opportunity for pharmaceuticals CMO/CDMO orders to be undertaken by PKU BIO.